![]() |
市場調查報告書
商品編碼
1422201
溶瘤病毒治療市場 - 2023-2031 年成長、未來前景、競爭分析Oncolytic Virus Therapy Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031 |
由於技術創新、應用範圍擴大和強大的研究前景,預計 2024 年至 2032 年預測期內,溶瘤病毒治療市場將以 27.5% 的複合年增長率成長。重組 Oncolyte 病毒、Oncolyte 野生型病毒以及實體瘤和黑色素瘤的標靶應用正在定義治療前景。儘管面臨挑戰,醫療保健專業人士、研究人員和行業領導者的集體努力正在使市場走上樂觀的軌道。區域動態凸顯了北美和亞太地區在塑造市場未來的重要性。競爭趨勢凸顯關鍵參與者的策略策略,增強市場競爭力。在預測期內,溶瘤病毒治療市場預計將見證變革性的市場發展,並重申其在腫瘤學領域的重要性。
使用基因工程溶瘤病毒是癌症治療中令人興奮的前沿領域。這些病毒經過專門設計,可以選擇性地靶向癌細胞,同時保護健康組織,從而最大限度地減少與傳統治療相關的副作用。具有增強腫瘤特異性、增強複製能力和增強治療有效負載的新興本土病毒的市場發展正在推動該市場向前發展。臨床試驗的證據強調了這些病毒在多種癌症類型中的有效性和安全性,激發了研究人員和臨床醫生的樂觀情緒。
儘管取得了有希望的進展,但在不同患者群體中實現統一的治療反應仍然存在挑戰。個別免疫反應的變化、腫瘤異質性和癌症的演變性質為溶瘤病毒治療的標準化治療結果帶來了障礙。有證據顯示某些患者的反應有限,凸顯了個別化治療策略的必要性。克服這些挑戰需要更深入地了解病毒、腫瘤和免疫系統之間的複雜相互作用。
2023年,基因改造病毒和野生型病毒在溶瘤病毒治療市場中都佔據了重要的收入份額。基因改造病毒佔據了壓倒性的市場份額,反映出癌症治療客製化的趨勢。預計 2024 年至 2032 年,由於持續的研究努力和經過驗證的功效,基因工程病毒將繼續佔據主導地位。然而,我們預期溶劑化的野生型病毒會獲得關注,特別是在病毒的固有特性與治療目標相符的應用中。
2023年,涵蓋多種癌症類型的實體癌症將成為溶瘤病毒治療的主要用途。實體瘤應用在預測期內具有最高的收入和複合年增長率,凸顯了該療法的廣泛用途。黑色素瘤的特徵是治療難度大,但已顯示出顯著的增長,並且在複合年增長率方面處於領先地位。黑色素瘤的獨特特徵,包括其免疫原性,使其成為溶瘤病毒治療的理想候選者。
醫院、專科診所和癌症研究機構是塑造溶瘤病毒治療市場的主要最終用戶。2023 年,醫院的收入和複合年增長率均處於領先地位,反映出它們在提供全面癌症護理方面的核心作用。專科診所由於採用密集的癌症治療方法而顯示出較高的複合年增長率。處於技術創新前沿的癌症研究機構為治療的進步做出了重大貢獻。這項預測凸顯了醫院的持續主導地位,專科診所的顯著成長。
北美憑藉強大的醫療基礎設施和大量的研究投入,2023年的銷售額比率和複合年增長率均排名第一。該地區對創新和合作研究措施的承諾為市場擴張創造了有利的環境。在歐洲,雖然複合年增長率較高,但銷售額比例略落後於北美。亞太地區的複合年增長率最高,代表尚未開發的潛力,醫療保健市場快速成長,人們對先進治療的認識不斷增強。中東和非洲地區市場貢獻較小,影響區域動態的因素較多。
包括製藥巨頭和創新生物技術公司在內的領先公司正在戰略聯盟和技術進步所塑造的市場格局中航行。到 2023 年,這些參與者將公佈可觀的收入,預計 2024 年至 2032 年將進一步成長。Amgen、Genelux Corporation、Oncolytics Biotech、Sorrento Therapeutics、Transgene SA、Daiichi Sankyo Company、Shanghai Sunway Biotech Co Ltd、Takara Bio Inc.、PsiOxus Therapeutics、SillaJen Inc.、ViroCure等領先公司採取了多元化的策略。市場地位。與研究機構合作、擴大產品組合以及投資臨床試驗是推動這些公司前進的關鍵策略舉措。
The oncolytic virus therapy market is expected to grow at a CAGR of 27.5% during the forecast period of 2024 to 2032, driven by technological innovations, expanding applications, and a robust research landscape. Genetically engineered oncolytic viruses, oncolytic wild-type viruses, and targeted applications for solid tumors and melanoma define the therapeutic landscape. While challenges persist, the market's trajectory is optimistic, propelled by the collective efforts of healthcare professionals, researchers, and industry leaders. Regional dynamics underscore the importance of North America and the Asia-Pacific in shaping the market's future. Competitive trends highlight the strategic maneuvers of key players, reinforcing the market's competitive nature. As the forecast period unfolds, the oncolytic virus therapy market is expected to witness transformative developments, reaffirming its significance in the oncology domain.
The use of genetically engineered oncolytic viruses represents a groundbreaking frontier in cancer treatment. These viruses are tailored to selectively target cancer cells while sparing healthy tissues, minimizing side effects associated with traditional therapies. The development of engineered viruses with enhanced tumor specificity, increased replication capacity, and augmented therapeutic payloads has propelled the market forward. Evidence from clinical trials highlights the efficacy and safety of these viruses in various cancer types, fostering optimism among researchers and clinicians.
Beyond engineered viruses, oncolytic wild-type viruses have emerged as key players in oncolytic virus therapy. These naturally occurring viruses exhibit inherent oncolytic properties, and ongoing research is uncovering their potential in cancer treatment. The adaptability of wild-type viruses to different tumor microenvironments and their ability to induce immunogenic cell death contribute to their therapeutic effectiveness. Evidence-based studies showcase the diverse applications of oncolytic wild-type viruses, providing a compelling narrative for their continued integration into cancer treatment protocols.
The increasing prevalence of solid tumors, coupled with the rising incidence of melanoma, has directed the spotlight toward these specific applications of oncolytic virus therapy. Clinical successes in treating solid tumors, including breast, lung, and colorectal cancers, underscore the therapy's potential across a spectrum of malignancies. Melanoma, notorious for its resistance to conventional treatments, has witnessed remarkable responses to oncolytic virus therapy, paving the way for tailored interventions. An in-depth analysis of market data from 2023 reveals the dominance of solid tumor applications, with melanoma exhibiting the highest CAGR during the forecast period.
Despite the promising advancements, challenges persist in achieving uniform therapeutic responses across diverse patient populations. Variability in individual immune responses, tumor heterogeneity, and the evolving nature of cancer present hurdles in standardizing oncolytic virus therapy outcomes. Evidence points to instances where certain patients exhibit limited responsiveness, emphasizing the need for personalized treatment strategies. Overcoming these challenges requires a deeper understanding of the complex interactions between viruses, tumors, and the immune system.
In 2023, the oncolytic virus therapy market witnessed a significant revenue share from both genetically engineered and wild-type viruses. Genetically engineered viruses dominated the landscape, reflecting the ongoing trend of customization in cancer treatment. The forecast for 2024 to 2032 anticipates a continued dominance of genetically engineered viruses, driven by sustained research efforts and their proven efficacy. However, oncolytic wild-type viruses are expected to gain momentum, particularly in applications where their natural attributes align with therapeutic goals.
Solid tumors, encompassing a range of cancer types, emerged as the primary application of oncolytic virus therapy in 2023. The highest revenue and CAGR during the forecast period are attributed to solid tumor applications, emphasizing the broad utility of this therapy. Melanoma, characterized by its challenging treatment landscape, exhibited substantial growth, positioning itself as a frontrunner in terms of CAGR. The distinct characteristics of melanoma, including its immunogenic nature, make it an ideal candidate for oncolytic virus therapy.
Hospitals, specialty clinics, and cancer research institutes constitute key end-users shaping the oncolytic virus therapy market. In 2023, hospitals led in both revenue generation and CAGR, reflecting their central role in providing comprehensive cancer care. Specialty clinics demonstrated a high CAGR, driven by their focused approach to cancer treatment. Cancer research institutes, at the forefront of innovation, contributed significantly to the therapy's development. The forecast underscores the sustained dominance of hospitals, with specialty clinics experiencing notable growth.
North America, with its robust healthcare infrastructure and substantial research investments, led in both the highest revenue percentage and CAGR in 2023. The region's commitment to technological innovation and collaborative research initiatives fosters a favorable environment for market expansion. Europe, while demonstrating a commendable CAGR, lagged slightly behind North America in revenue percentage. The Asia-Pacific region, marked by burgeoning healthcare markets and increasing awareness of advanced therapies, exhibited the highest CAGR, indicating untapped potential. The Middle East and Africa contributed modestly to the market, with diverse factors influencing regional dynamics.
Top players in the oncolytic virus therapy market, including pharmaceutical giants and innovative biotech firms, navigate a landscape shaped by strategic collaborations and technological advancements. In 2023, these players reported substantial revenues, with projections for the 2024 to 2032 period indicating further growth. Leading companies, such as Amgen, Genelux Corporation, Oncolytics Biotech, Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc. and ViroCure, employed diverse strategies to maintain their market positions. Collaborations with research institutions, expansion of product portfolios, and investments in clinical trials are key strategic initiatives driving these companies forward.
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofOncolytic Virus Therapy market are as follows:
Micro and macro environment factors that are currently influencing the Oncolytic Virus Therapy market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
TABLE 3 Global Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 4 Global Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 6 Global Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 7 Global Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 10 North America Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 11 North America Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 13 North America Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 14 North America Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 17 U.S. Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 18 U.S. Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 20 U.S. Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 21 U.S. Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 24 Canada Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 25 Canada Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 27 Canada Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 28 Canada Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 31 Rest of North America Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 32 Rest of North America Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 34 Rest of North America Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 35 Rest of North America Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 38 UK and European Union Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 39 UK and European Union Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 41 UK and European Union Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 42 UK and European Union Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 45 UK Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 46 UK Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 48 UK Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 49 UK Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 52 Germany Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 53 Germany Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 55 Germany Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 56 Germany Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 59 Spain Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 60 Spain Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 62 Spain Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 63 Spain Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 66 Italy Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 67 Italy Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 69 Italy Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 70 Italy Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 73 France Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 74 France Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 76 France Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 77 France Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 80 Rest of Europe Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 81 Rest of Europe Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 83 Rest of Europe Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 84 Rest of Europe Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 87 Asia Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 88 Asia Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 90 Asia Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 91 Asia Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 94 China Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 95 China Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 97 China Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 98 China Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 101 Japan Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 102 Japan Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 104 Japan Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 105 Japan Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 108 India Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 109 India Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 111 India Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 112 India Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 115 Australia Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 116 Australia Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 118 Australia Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 119 Australia Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 122 South Korea Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 123 South Korea Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 125 South Korea Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 126 South Korea Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 129 Latin America Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 130 Latin America Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 132 Latin America Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 133 Latin America Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 136 Brazil Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 137 Brazil Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 139 Brazil Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 140 Brazil Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 143 Mexico Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 144 Mexico Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 146 Mexico Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 147 Mexico Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 150 Rest of Latin America Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 151 Rest of Latin America Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 153 Rest of Latin America Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 154 Rest of Latin America Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 157 Middle East and Africa Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 158 Middle East and Africa Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 160 Middle East and Africa Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 161 Middle East and Africa Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 164 GCC Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 165 GCC Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 167 GCC Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 168 GCC Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 171 Africa Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 172 Africa Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 174 Africa Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 175 Africa Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
TABLE 178 Rest of Middle East and Africa Oncolytic Virus Therapy Market By Oncolytic Wild-type Viruses, 2022-2032, USD (Million)
TABLE 179 Rest of Middle East and Africa Oncolytic Virus Therapy Market By Application, 2022-2032, USD (Million)
TABLE 181 Rest of Middle East and Africa Oncolytic Virus Therapy Market By Melanoma, 2022-2032, USD (Million)
TABLE 182 Rest of Middle East and Africa Oncolytic Virus Therapy Market By End Use, 2022-2032, USD (Million)
FIG. 10Market Positioning of Key Oncolytic Virus Therapy Market Players, 2023
FIG. 11Global Oncolytic Virus Therapy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032